CMA mediates resistance in breast cancer models

BACKGROUND: Breast cancer (BC) is the most common malignancy in women and the second leading cause of cancer-related death; chemoresistance is still a clinical challenge mainly because of the different molecular features of this kind of tumour. Doxorubicin (Doxo) is widely used despite its adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Dico, Alessia, Martelli, C., Corsi, F., Porro, D., Ottobrini, L., Bertoli, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324152/
https://www.ncbi.nlm.nih.gov/pubmed/37407979
http://dx.doi.org/10.1186/s12935-023-02969-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324152/
https://www.ncbi.nlm.nih.gov/pubmed/37407979
http://dx.doi.org/10.1186/s12935-023-02969-9

Ejemplares similares